The Do’s & Don’ts of Flow Cytometry in the Clinic

Oct 22, 2020 11:00:00 AM / by Champions Oncology posted in Flow Cytometry, Flow Cytometry-based Receptor Occupancy

Clinical flow cytometry is now a standard tool used by clinical researchers in numerous fields, especially immuno-oncology. Consider these “Do’s & Don’ts” of clinical flow cytometry as you decide to use this tool for clinical research.

Read More →

Next Generation Sequencing: Revolutionizing Oncology Research One Base-Pair at a Time

Oct 13, 2020 3:10:13 PM / by Champions Oncology posted in NGS Technology, RNS-Seq, Next Generation Sequencing

Advances in oncology research have led to the development of personalized treatments based on specific knowledge of a patient’s tumor. New therapies have been customized to target signaling pathways that are hyperactivated or block specific variants of cell surface molecules, thus leading to better anti-tumor responses. Next generation sequencing (NGS) technology has been at the forefront of these breakthroughs by enabling researchers to rapidly sequence RNA transcripts (RNA-seq) or exons (whole exome sequencing; WES) within tumor tissue and translate these findings into novel therapies.

Read More →

Targeting DNA Damage in Cancer

Sep 3, 2020 10:05:00 AM / by Champions Oncology posted in DNA Damage

DNA Damage

DNA damage is one of the primary triggers of cancer development and has been linked to many types of cancers, including prostate, stomach, liver and skin cancers as well as leukemia. Within cells, the DNA sequence encodes all the instructions required for building proteins that are needed for cellular functions such as metabolism, replication, tissue and organ maintenance. The fidelity of the DNA sequence in a cell is maintained by multiple mechanisms but errors and mutations can occur, which sets off a chain of events that lead to tumor growth.

Read More →

Ex Vivo Expertise – Things to Consider when using Ex Vivo Systems for Hematologic Malignancies

Aug 20, 2020 9:15:00 AM / by Champions Oncology

Advances in precision medicine have transformed treatments for many types of solid tumors, but similar treatment options have been more limited for hematologic oncology. Now, new ex vivo models are being developed that use patient-derived lymphoma or leukemia cells for screening experimental drugs or biologics. Therapeutic antibody screening is well-suited to these platforms and can inform preclinical research decisions as well as clinical care.

Read More →

Better Options: Flow Cytometry as an In Vivo Model Endpoint

Aug 6, 2020 4:39:12 PM / by Champions Oncology

In vivo models for numerous diseases and conditions have endpoints that have involved animals being gravely ill or dying. As researchers have sought to utilize animal models in more humane and practical ways, surrogate endpoints have been developed that prevent animals from suffering and provide critical research data. Flow cytometry has been instrumental to these advances. Consider these aspects of preclinical flow cytometry endpoint analysis as you develop new protocols.

Read More →

Quantitative IHC: At the Cutting Edge of Molecular Pathology for Cancer Diagnostics

Jul 23, 2020 10:11:48 AM / by Champions Oncology

Molecular pathology has been used for decades together with anatomic pathology for disease diagnosis and evaluating treatment efficacy. Immunohistochemistry (IHC) has been a key technique used on molecular pathology that involves staining tissue sections with molecular markers and evaluating staining patterns that may correspond to different tumor stages or other disease pathologies.

Read More →

Developing Assays in Non-Human Primates (NHPs)

Jul 9, 2020 9:00:00 AM / by champions posted in Flow Cytometry

Non-human primates (NHPs) continue to be a valuable resource for preclinical research because of similarities they share with humans. NHPs, especially rhesus macaques, are used in preclinical studies for evaluating new drugs or vaccines for safety and efficacy. Flow cytometry assays can be easily adapted to study cells from NHP. Consider these three factors if you are planning to adapt a flow cytometry assay for use with NHP samples.

Read More →

Top 5 things to consider when outsourcing in vivo models

Jun 25, 2020 8:45:00 AM / by Champions Oncology posted in PDX Models

Most preclinical cancer studies are heavily dependent on in vivo (animal) models, especially those using genetically engineered mice. The hundreds of existing mouse models allow scientists to study specific tumor types, including tumors derived from patients (PDX), visualize different immune cell subsets in vivo, and screen large panels of potential drugs or biologics for anti-tumor properties.

Read More →

Receptor Occupancy and Flow Cytometry

Jun 11, 2020 9:00:00 AM / by Champions Oncology posted in Flow Cytometry, Receptor Occupancy

The development of new oncology treatments has focused on strategies that alter immune responses. Many of these novel therapies use antibodies that bind to receptors on different immune cell subsets and either activate or suppress their functions depending on the immune response being targeted. Antibody-drug conjugates are also becoming more widely used for improved targeting of drugs to specific cell subsets. Flow cytometry-based receptor occupancy (RO) assays are a valuable tool for quantifying cell surface expression of target molecules and are used to generate pharmacodynamic (PD) data, which can be used with pharmacokinetic (PK) data to guide dosing strategies. Consider these different types of receptor occupancy assays as you develop the most useful tools for screening therapeutic molecules.

Read More →

Immunohistochemistry in Cancer Research

May 28, 2020 11:21:51 AM / by Champions Oncology posted in Immunohistochemistry

Plasmacytoid carcinoma of the urinary bladder – H&E Staining

 

Immunohistochemistry (IHC) is a technique that originates in the early twentieth century but continues to be a valuable method that forms the backbone of molecular pathology. IHC is used for histological examination of tissues and specifically detects the presence of a molecule, such as a tumor antigen. IHC uses antibody-based labeling in which the primary antibody detects the target of interest and the secondary antibody detects the primary antibody which is linked to a molecule for microscopic visualization. Many different secondary antibody labeling modalities exist, including fluorescence, enzyme-mediated reactions and colloidal gold, and different labels are suited to specific microscopy platforms. Consider these five aspects of IHC as you implement this technique in preclinical cancer research:

Read More →